‘No’ urged for OTC sale of drug
From Times Wire Services
The government should reject Merck & Co. Inc.’s third bid to sell a cholesterol-lowering pill without a doctor’s prescription, an advisory panel ruled.
Advisors to the Food and Drug Administration voted 10 to 2 with one abstention against Merck’s proposal for a low-dose, over-the-counter version of its cholesterol fighter Mevacor.
FDA officials usually follow the panel’s recommendations.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
